Publications by authors named "Luoting Yu"

Claim this Profile
D
Design, synthesis and biological evaluation of 8-phenylquinazolin-2-amine derivatives as FLT3 covalent inhibitors targeting cysteine 828 in the ATP pocket.
Wei Wei, Zuli Hu, Jiuyu Gao, Tianqiong Yang, Qi Zhang, Lin Yue, Ningyu Wang, Yu Cao, Luoting Yu

Eur J Med Chem· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel indazole derivatives as type Ⅰ PRMTs inhibitors for the treatment of triple-negative breast cancer.
Qiangsheng Zhang, Shuyan Zhou, Xueying Chen, Luoting Yu, Xianli Zhou

Eur J Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological evaluation of a bioavailable EZH2 PROTAC with a 2,8-diazaspiro[4.5]decane linker.
Wei Wei, Tianqiong Yang, Ziqiao Zhao, Kun Huang, Longyue Tao, Yuanle Deng, Luoting Yu

Bioorg Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Potent and Selective Focal Adhesion Kinase Proteolysis Targeting Chimera: Targeting Noncatalytic Functions of Focal Adhesion Kinase to Facilitate Antitumor Immunity.
Wei Wei, Guangmei Li, Zuli Hu, Xiang Hu, Rong Hu, Xinyue Li, Jiuyu Gao, Yu Cao, Luoting Yu

J Med Chem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1,3-Disubstituted Pyrazole derivatives as Mycobacterium tuberculosis inhibitors.
Guoquan Wan, Chao Gao, Xiaorui Zhang, Huapei Qiu, Qifan Tang, Luoting Yu

Bioorg Med Chem Lett· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An updated patent review of EZH2 inhibitors (2024-present).
Guoquan Wan, Siyan Li, Qifan Tang, Huapei Qiu, Qiangsheng Zhang, Luoting Yu

Expert Opin Ther Pat· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and biological evaluation of 3-amino-6-(2-hydroxyphenyl)pyridazin-4-aryl derivatives as SMARCA2/4 degraders.
Tianqiong Yang, Wei Wei, Qi Zhang, Xin Chen, Kaiyan Xu, Lin Yue, Jiuyu Gao, Ningyu Wang, Yu Cao, Luoting Yu

Eur J Med Chem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent FLT3 Inhibitor ()-4-(3-(3-Fluoro-4-(morpholinomethyl)styryl)-1-indazol-6-yl)pyridin-2-amine for the Treatment of Acute Myeloid Leukemia with Multiple FLT3 Mutations.
Zhihao Liu, Ying Xu, Wei Wei, Zuli Hu, Jiuyu Gao, Longyue Tao, Lin Yue, Ningyu Wang, Yu Cao, Luoting Yu

J Med Chem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplified flow cytometry-based assay for rapid multi-cytokine profiling and machine-learning-assisted diagnosis of inflammatory diseases.
Qiang Quan, Xuegui Ju, Guangmei Li, Lu Ye, Sichong Ren, Ruyue Lin, Luoting Yu

Front Pharmacol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covalent inhibitors meet epigenetics: New opportunities.
Qiang Feng, Luoting Yu, Lu Li, Qiangsheng Zhang

Eur J Med Chem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel selective FAK inhibitor E2 inhibits ovarian cancer metastasis and growth by inducing cytotoxic autophagy.
Zhanzhan Feng, Wei Wei, Shirui Wang, Xiao Li, Lifeng Zhao, Luoting Yu

Biochem Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2 gatekeeper mutation based on a pan-FGFR inhibitor.
Zuli Hu, Qiangsheng Zhang, Zulong Li, Hongling Yang, Xin Chen, Luoting Yu

Eur J Med Chem· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a first-in-class degrader for the protein arginine methyltransferase 6 (PRMT6).
Hongling Yang, Qiangsheng Zhang, Shuyan Zhou, Zuli Hu, Qing Tang, Luoting Yu

Bioorg Chem· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting type I PRMTs as promising targets for the treatment of pulmonary disorders: Asthma, COPD, lung cancer, PF, and PH.
Shuyan Zhou, Qiangsheng Zhang, Honglin Yang, Yongxia Zhu, Xiang Hu, Luoting Yu

Life Sci· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell RNA sequencing reveals diverse B cell phenotypes in patients with anti-NMDAR encephalitis.
Sisi Li, Xiang Hu, Minjin Wang, Luoting Yu, Qi Zhang

Psychiatry Clin Neurosci· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer.
Hualong He, Wan Yang, Yaojie Shi, Xin Chen, Xinyi Chen, Xinyue Li, Yingyue Yang, Ningyu Wang, Luoting Yu

Eur J Med Chem· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TTK inhibition activates STING signal and promotes anti-PD1 immunotherapy in breast cancer.
Xiang Hu, Guangmei Li, Sisi Li, Qiwei Wang, Yuerong Wang, Luoting Yu

Biochem Biophys Res Commun· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants.
Yingyue Yang, Xiaojie He, Zulong Li, Kai Ran, Ningyu Wang, Luoting Yu

Eur J Med Chem· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis.
Wang Xiang, Hualong He, Xianjie Duan, Zhiqun He, Xinyue Xu, Luoting Yu

Microbiol Spectr· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is repeat sentinel lymph node biopsy possible for surgical axillary staging among patients with ipsilateral breast tumor recurrence?
Xunxi Lu, Mengting He, Luoting Yu, Zongchao Gou

Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity.
Xiao Li, Jia Wang, Qianqian Wang, Tianwen Luo, Xuejiao Song, Xinyu You, Luoting Yu

Heliyon· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo.
Yongxia Zhu, Lidan Zhang, Xuejiao Song, Qiangsheng Zhang, Ting Wang, Luoting Yu

Biochem Pharmacol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A patent review of EZH2 inhibitors from 2017 and beyond.
Guoquan Wan, Huan Feng, Chang Su, Yongxia Zhu, Lidan Zhang, Luoting Yu

Expert Opin Ther Pat· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and evaluation of antitumor activity of selective PRMT6 inhibitors.
Qiangsheng Zhang, Jiaying Cao, Yiqian Zhang, Zhenfei Bi, Qiang Feng, Luoting Yu

Eur J Med Chem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer.
Qiangsheng Zhang, Xinyi Chen, Jiaying Cao, Wan Yang, Guoquan Wan, Ningyu Wang, Luoting Yu

J Med Chem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis